These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 6188894)

  • 1. Precipitation by yohimbine of the withdrawal syndromes of clonidine, guanfacine, and methyldopa in the spontaneously hypertensive rat.
    Thoolen MJ; Hendriks JC; Timmermans PB; van Zwieten PA
    J Cardiovasc Pharmacol; 1983; 5(2):224-8. PubMed ID: 6188894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Guanfacine and clonidine: antihypertensive and withdrawal characteristics after continuous infusion and its interruption in the spontaneously hypertensive and normotensive rat.
    Thoolen MJ; Timmermans PB; van Zwieten PA
    Naunyn Schmiedebergs Arch Pharmacol; 1982 Apr; 319(1):82-6. PubMed ID: 7050735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The hypotensive activity and side effects of methyldopa, clonidine, and guanfacine.
    van Zwieten PA; Thoolen MJ; Timmermans PB
    Hypertension; 1984; 6(5 Pt 2):II28-33. PubMed ID: 6094346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Withdrawal reactions following cessation of central alpha-adrenergic receptor agonists.
    Reid JL; Campbell BC; Hamilton CA
    Hypertension; 1984; 6(5 Pt 2):II71-5. PubMed ID: 6150002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of the inhibitory effects of clonidine and guanfacine on the behavioral and autonomic components of morphine withdrawal in rats.
    Buccafusco JJ; Marshall DC; Turner RM
    Life Sci; 1984 Sep; 35(13):1401-8. PubMed ID: 6148677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Yohimbine-precipitated clonidine withdrawal: an experimental model of the antihypertensive drug withdrawal syndrome.
    Penning DH; Jhamandas K
    Can J Physiol Pharmacol; 1992 Jun; 70(6):853-8. PubMed ID: 1358421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effects of guanfacine on pre- and postsynaptic alpha-adrenoceptors studied in comparison with those of clonidine].
    Nakagawa Y; Chin W; Imai S
    Nihon Yakurigaku Zasshi; 1982 May; 79(5):431-9. PubMed ID: 6127290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuous infusion and withdrawal of methyldopa in the spontaneously hypertensive rat.
    Thoolen MJ; Hendriks JC; Timmermans PB; van Zwieten PA
    J Cardiovasc Pharmacol; 1983; 5(2):221-3. PubMed ID: 6188893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of guanfacine versus clonidine for efficacy, safety and occurrence of withdrawal syndrome in step-2 treatment of mild to moderate essential hypertension.
    Wilson MF; Haring O; Lewin A; Bedsole G; Stepansky W; Fillingim J; Hall D; Roginsky M; McMahon FG; Jagger P
    Am J Cardiol; 1986 Mar; 57(9):43E-49E. PubMed ID: 3513530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies on clonidine and guanfacine withdrawal after short term treatment in the rat.
    Barber ND; Reid JL
    Arch Int Pharmacodyn Ther; 1982 Sep; 259(1):112-8. PubMed ID: 6758716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Location of the mechanism of the clonidine withdrawal tachycardia in rats.
    Jonkman FA; Man PW; Thoolen MJ; van Zwieten PA
    J Pharm Pharmacol; 1985 Aug; 37(8):580-2. PubMed ID: 2864424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacology of centrally acting hypotensive drugs.
    van Zwieten PA
    Br J Clin Pharmacol; 1980; 10 Suppl 1(Suppl 1):13S-20S. PubMed ID: 6104975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of antihypertensive activity and tolerability of guanfacine and methyldopa.
    Malini PL; Strocchi E; Ambrosioni E; Magnani B
    Int J Clin Pharmacol Res; 1983; 3(1):35-9. PubMed ID: 6384071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clonidine and guanfacine in hypertension.
    Jain AK; Hiremath A; Michael R; Ryan JR; McMahon FG
    Clin Pharmacol Ther; 1985 Mar; 37(3):271-6. PubMed ID: 3882307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Guanfacine and other centrally acting drugs in antihypertensive therapy; pharmacological and clinical aspects.
    Saameli K; Jerie P; Scholtysik G
    Clin Exp Hypertens A; 1982; 4(1-2):209-19. PubMed ID: 6280899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Double-blind trial comparing guanfacine and methyldopa in patients with essential hypertension.
    Bune AJ; Chalmers JP; Graham JR; Howe PR; West MJ; Wing LM
    Eur J Clin Pharmacol; 1981; 19(5):309-15. PubMed ID: 7016550
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical experience with guanfacine in long-term treatment of hypertension. Part II: adverse reactions to guanfacine.
    Jerie P
    Br J Clin Pharmacol; 1980; 10 Suppl 1(Suppl 1):157S-164S. PubMed ID: 6994770
    [No Abstract]   [Full Text] [Related]  

  • 18. Possible role of an endogenous opiate in the cardiovascular effects of central alpha adrenoceptor stimulation in spontaneously hypertensive rats.
    Farsang C; Ramirez-Gonzalez MD; Mucci L; Kunos G
    J Pharmacol Exp Ther; 1980 Jul; 214(1):203-8. PubMed ID: 6248627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of alpha 2-agonists on morphine withdrawal behaviour: potentiation of jumping mediated by alpha 2-receptors.
    van der Laan JW
    Naunyn Schmiedebergs Arch Pharmacol; 1985 May; 329(3):293-8. PubMed ID: 2862592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alpha-adrenergic receptors and blood pressure control.
    Reid JL
    Am J Cardiol; 1986 Mar; 57(9):6E-12E. PubMed ID: 2869681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.